Nicole LaBrosse's most recent trade in Halozyme Therapeutics Inc. was a trade of 6,688 Common Stock done . Disclosure was reported to the exchange on Feb. 23, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 6,688 | 35,501 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 6,688 | 20,063 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.75 per share. | 23 Feb 2025 | 3,601 | 31,900 (0%) | 0% | 57.8 | 207,958 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 22,603 | 22,603 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 21,327 | 21,327 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 17,409 | 33,402 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 17,409 | 0 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 9,400 | 24,002 (0%) | 0% | 58.3 | 547,926 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 5,329 | 31,682 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 5,329 | 10,658 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 5,093 | 5,093 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 5,093 | 29,095 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 2,869 | 28,813 (0%) | 0% | 58.3 | 167,234 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 2,742 | 26,353 (0%) | 0% | 58.3 | 159,831 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,254 | 16,734 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 1,254 | 0 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 741 | 15,993 (0%) | 0% | 58.3 | 43,193 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 28,662 | 28,662 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 6,935 | 6,935 | - | - | Performance Stock Unit | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 6,050 | 17,409 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 5,221 | 8,184 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2024 | 5,000 | 0 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 53.85 per share. | 22 Jul 2024 | 4,008 | 15,480 (0%) | 0% | 53.9 | 215,843 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.50 per share. | 22 Jul 2024 | 4,008 | 19,488 (0%) | 0% | 22.5 | 90,180 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 54.25 per share. | 22 Jul 2024 | 992 | 15,480 (0%) | 0% | 54.3 | 53,819 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.50 per share. | 22 Jul 2024 | 992 | 16,472 (0%) | 0% | 22.5 | 22,320 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.50 per share. | 26 Jun 2024 | 10,000 | 25,480 (0%) | 0% | 22.5 | 225,000 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2024 | 10,000 | 5,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2024 | 10,000 | 15,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jun 2024 | 10,000 | 25,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 52.04 per share. | 26 Jun 2024 | 10,000 | 15,480 (0%) | 0% | 52.0 | 520,400 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.50 per share. | 26 Jun 2024 | 10,000 | 25,480 (0%) | 0% | 22.5 | 225,000 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 51.93 per share. | 26 Jun 2024 | 10,000 | 15,480 (0%) | 0% | 51.9 | 519,340 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.50 per share. | 26 Jun 2024 | 10,000 | 25,480 (0%) | 0% | 22.5 | 225,000 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 51.82 per share. | 26 Jun 2024 | 10,000 | 15,480 (0%) | 0% | 51.8 | 518,200 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 27,722 | 27,722 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2024 | 26,751 | 26,751 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 5,329 | 18,344 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 5,329 | 15,987 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 5,093 | 10,186 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2024 | 5,093 | 15,752 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.10 per share. | 16 Feb 2024 | 2,864 | 15,480 (0%) | 0% | 36.1 | 103,390 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.10 per share. | 16 Feb 2024 | 2,737 | 13,015 (0%) | 0% | 36.1 | 98,806 | Common Stock |
| Halozyme Therapeutics Inc. | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 1,254 | 11,345 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2024 | 1,254 | 1,254 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.91 per share. | 15 Feb 2024 | 686 | 10,659 (0%) | 0% | 35.9 | 24,634 | Common Stock |
| Halozyme Therapeutics Inc. | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 2,502 | 11,568 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2024 | 2,502 | 0 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | LaBrosse Nicole | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 35.49 per share. | 10 Feb 2024 | 1,477 | 10,091 (0%) | 0% | 35.5 | 52,419 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 61,061 | 61,061 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 21,316 | 21,316 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 5,094 | 11,591 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2023 | 5,094 | 15,279 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 49.26 per share. | 16 Feb 2023 | 2,525 | 9,066 (0%) | 0% | 49.3 | 124,382 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 1,254 | 7,118 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2023 | 1,254 | 2,508 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 49.20 per share. | 15 Feb 2023 | 621 | 6,497 (0%) | 0% | 49.2 | 30,553 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,503 | 6,548 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 2,503 | 2,502 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.92 per share. | 10 Feb 2023 | 1,392 | 5,156 (0%) | 0% | 48.9 | 68,097 | Common Stock |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,389 | 6,545 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,389 | 0 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc. | Nicole LaBrosse | SVP, CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 48.92 per share. | 10 Feb 2023 | 681 | 5,864 (0%) | 0% | 48.9 | 33,315 | Common Stock |